|
|||||
|
|
Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept,tocilizumab, or rituximab: results from the Italian GISEA registry |
|
| Authors: | Sebastiani Marco Venerito Vincenzo Bugatti Serena Bazzani Chiara Biggioggero Martina Petricca Luca Foti Rosario Bortoluzzi Alessandra Balduzzi Silvia Visalli Elisa Frediani Bruno Manfredi Andreina Gremese Elisa Favalli Ennio Iannone Florenzo Ferraccioli Gianfranco Lapadula Giovanni |
| Affiliation: | 1.Rheumatology Unit, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria Policlinico di Modena, Via del Pozzo, 41125, Modena, Italy ;2.Department of Emergency and Organ Transplantation, Rheumatology Unit, University of Bari, Bari, Italy ;3.Division of Rheumatology, IRCCS Policlinico San Matteo Foundation, University of Pavia, Pavia, Italy ;4.Unit of Rheumatology and Clinical Immunology, ASST Spedali Civili, Brescia, Italy ;5.Department of Rheumatology, Gaetano Pini Institute, Milan, Italy ;6.Division of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy ;7.Rheumatology Unit, A.O.U. Policlinico San Marco, Catania, Italy ;8.Section of Rheumatology, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliera-Universitaria di Ferrara, Ferrara, Italy ;9.Rheumatology Unit, Department of Medical Sciences, Surgery e Neurosciences, University of Siena, Siena, Italy ; |
| Abstract: | Clinical Rheumatology - EULAR recommendations do not suggest which biologic disease-modifying anti-rheumatic drug (bDMARD) should be preferred after failure of a first bDMARD in the treatment of... |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |